Table 5.
Anti-Emetics of Educational Interest
| Agent | All Healthcare Providers, %* | Hematology/Oncology Physicians, % | Hematology/Oncology Nurses, % |
|---|---|---|---|
| APF530 (subcutaneous granisetron) | 77 | 87 | 90 |
| Aprepitant combinations | 81 | 94 | 98 |
| Cannabinoids | 79 | 80 | 89 |
| Fosaprepitant combinations | 80 | 93 | 97 |
| Gabapentin | 86 | 85 | 94 |
| Netupitant/palonosetron fixed-dose combination | 80 | 92 | 96 |
| Olanzapine | 83 | 92 | 94 |
| Palonosetron combinations | 80 | 93 | 93 |
| Rolapitant | 80 | 89 | 94 |
| Transdermal granisetron | 83 | 91 | 96 |
*
Percentages in all categories refer to the percentage of healthcare providers who reported being “strongly” or “somewhat interested” in learning about an agent.